Evidence map›Paper›PMID 17601208›Full record

ReviewActa otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale2007

Group A streptococcus and its antibiotic resistance.

D Passàli, M Lauriello, G C Passàli, F M Passàli, L Bellussi

Open access · greenAbstract readReview
In one paragraph

Review in Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Group AOman medical journal · 2021
    Review
  10. Article
  11. Article
  12. Article
  13. Synergy and Mode of Action of Ceftazidime plus Quercetin or Luteolin on Streptococcus pyogenes.Evidence-based complementary and alternative medicine : eCAM · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

D PassàliENT Clinic, University of Siena, Italy. d.passali@virgilio.it
M Lauriello
G C Passàli
F M Passàli
L Bellussi
University of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute pharyngo-tonsillitis caused by beta-haemolytic group A Streptococcus is a common disease in childhood. Epithelial cells are the initial sites of the host invasion by group A Streptococcus. Although group A Streptococcus has been considered an extracellular pathogen, recent studies have demonstrated that strains of this bacterium can internalize into epithelial cells both in vitro and in vivo. As adherence to and internalization into host cells significantly contributes to the pathogenesis of group A Streptococcus infections, internalization of group A Streptococcus by human epithelial cells has been extensively studied during the past decade. Multiple mechanisms are involved in this process. Most strains of Streptococcus pyogenes express the fibronectin-binding proteins F1 and F2, which promote bacterial adherence to and entry into human cells. Strains containing the gene for the protein Fl have been proved to be responsible for the failure of antibiotic treatment to eradicate Streptococcus pyogenes. Thus, in a significant number of cases, streptococcal internalization might contribute to eradication failure and persistent throat carriage. Since treatment failure, asymptomatic group A Streptococcus carriers and recurrent group A Streptococcus infections represent the main group A Streptococcus reservoir, from which the bacteria are spread in the general population, the choice of antibiotic is crucial. Beta-lactams select a large number of F1-positive organisms: therefore, macrolides, and, possibly, last generation molecules, are the best and first choice for antibiotic treatment against group A Streptococcus.

Indexed as

Drug Resistance, BacterialAnti-Bacterial AgentsHumansStreptococcal InfectionsStreptococcus pyogenesAnti-Bacterial Agents

Identifiers

PMID17601208
PMCPMC2640020
OpenAlexW1695404967

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.